Date: 2015-04-06
Type of information: Grant
Company: Iteos Therapeutics (Belgium) ImaBiotech (France)
Investors: Walloon Region (Belgium) Bpifrance (France)
Amount: €0.8 million
Funding type: grant
Planned used: The grant will be used to fund joint research programs over the next two years to characterize tumor tissue microenviroment through the combination of the unique capabilities of the two companies. ITeos will pursue its focus on immunomodulation-based cancer immunotherapy strategies by contributing immune-oncology animal models and tissue libraries for metabolite profiling through Multimaging™(combined Mass Spectrometry Imaging and Immuno-histology) technology of ImaBiotech. The companies will share the results by having iTeos receive all rights to the therapeutic applications of the research while ImaBiotech receives the rights to all diagnostic applications and pharmacology studies.
Others: * On April 6, 2015, Iteos Therapeutics and ImaBiotech announced that they will receive 800,000 euro from Walloon, Belgium and BPI, France, to fund joint research programs over the next two years to characterize tumor tissue microenviroment through the combination of the unique capabilities of the two companies.
Therapeutic area:
